$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000155837024011453 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$7.423M	$6.255M
YoY Change	111.0%	1.67%
Cost Of Revenue	$3.546M	$3.499M
YoY Change	21.94%	-14.2%
Gross Profit	$3.877M	$2.756M
YoY Change	535.57%	32.88%
Gross Profit Margin	52.23%	44.06%
Selling, General & Admin	$10.46M	$12.14M
YoY Change	-0.28%	11.64%
% of Gross Profit	269.82%	440.38%
Research & Development	$5.446M	$6.810M
YoY Change	-3.87%	30.41%
% of Gross Profit	140.47%	247.1%
Depreciation & Amortization	$2.128M	$1.838M
YoY Change	71.61%	50.78%
% of Gross Profit	54.89%	66.69%
Operating Expenses	$15.91M	$18.95M
YoY Change	-1.54%	17.73%
Operating Profit	-$12.03M	-$16.19M
YoY Change	-22.62%	15.49%
Interest Expense	$212.0K	$3.834M
YoY Change	-71.35%	136.52%
% of Operating Profit
Other Income/Expense, Net	-$313.0K	$2.581M
YoY Change	68.28%	-200.62%
Pretax Income	-$12.34M	-$13.61M
YoY Change	-21.54%	-17.94%
Income Tax	-$13.00K	$0.00
% Of Pretax Income
Net Earnings	-$12.33M	-$13.61M
YoY Change	-21.62%	-17.94%
Net Earnings / Revenue	-166.11%	-217.59%
Basic Earnings Per Share	$0.25	$0.08
Diluted Earnings Per Share	$0.25	$0.08
COMMON SHARES
Basic Shares Outstanding	30.03M	29.92M
Diluted Shares Outstanding	40.42M	39.83M

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.41M	$23.80M
YoY Change	-62.96%	-55.1%
Cash & Equivalents	$15.55M	$22.94M
Short-Term Investments	$863.0K	$859.0K
Other Short-Term Assets
YoY Change
Inventory	$4.742M	$5.133M
Prepaid Expenses
Receivables	$4.948M	$6.731M
Other Receivables	$3.428M	$3.679M
Total Short-Term Assets	$29.53M	$39.34M
YoY Change	-47.47%	-40.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.235M	$1.334M
YoY Change	23.62%	63.28%
Goodwill	$57.43M	$57.43M
YoY Change	37.91%	37.91%
Intangibles	$20.34M	$22.35M
YoY Change	211.01%	191.04%
Long-Term Investments
YoY Change
Other Assets	$114.0K	$140.0K
YoY Change	14.0%	-20.45%
Total Long-Term Assets	$80.43M	$82.79M
YoY Change	59.91%	61.13%
TOTAL ASSETS
Total Short-Term Assets	$29.53M	$39.34M
Total Long-Term Assets	$80.43M	$82.79M
Total Assets	$110.0M	$122.1M
YoY Change	3.24%	4.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.462M	$9.826M
YoY Change	15.92%	37.58%
Accrued Expenses	$596.0K	$884.0K
YoY Change	496.0%	509.66%
Deferred Revenue	$1.118M	$1.515M
YoY Change	63.45%	92.02%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.670M	$5.191M
YoY Change
Total Short-Term Liabilities	$18.85M	$17.42M
YoY Change	132.49%	115.65%
LONG-TERM LIABILITIES
Long-Term Debt	$20.19M	$23.44M
YoY Change	-30.39%	-19.43%
Other Long-Term Liabilities	$49.00K	$51.00K
YoY Change	36.11%	41.67%
Total Long-Term Liabilities	$32.60M	$36.66M
YoY Change	7.35%	19.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.85M	$17.42M
Total Long-Term Liabilities	$32.60M	$36.66M
Total Liabilities	$51.44M	$54.08M
YoY Change	33.72%	39.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$378.1M	-$363.5M
YoY Change	13.25%	14.68%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$58.51M	$68.06M
YoY Change
Total Liabilities & Shareholders Equity	$110.0M	$122.1M
YoY Change	3.24%	4.25%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$12.33M	-$13.61M
YoY Change	-21.62%	-17.94%
Depreciation, Depletion And Amortization	$2.128M	$1.838M
YoY Change	71.61%	50.78%
Cash From Operating Activities	-$7.357M	-$11.36M
YoY Change	-14.95%	17.92%
INVESTING ACTIVITIES
Capital Expenditures	$32.00K	$29.00K
YoY Change	-88.57%	-80.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$32.00K	-$29.00K
YoY Change	-88.57%	-100.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-7.357M	-11.36M
Cash From Investing Activities	-32.00K	-29.00K
Cash From Financing Activities	0.000	0.000
Net Change In Cash	-7.389M	-11.39M
YoY Change	-15.36%	-181.48%
FREE CASH FLOW
Cash From Operating Activities	-$7.357M	-$11.36M
Capital Expenditures	$32.00K	$29.00K
Free Cash Flow	-$7.389M	-$11.39M
YoY Change	-17.26%	16.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Entity Central Index Key EntityCentralIndexKey	0001533998
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30024275
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27191849
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	18959
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	40331
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
CY2023Q2	us-gaap	Investment Variable Interest Rate Type Extensible Enumeration InvestmentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#PrimeRateMember
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37704
	dei	Entity Registrant Name EntityRegistrantName	DarioHealth Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2973162
	dei	Entity Address Address Line1 EntityAddressAddressLine1	322 W. 57th St. #33B
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	972
	dei	Local Phone Number LocalPhoneNumber	770-6377
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	DRIO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30028280
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22938000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36797000
CY2024Q2	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	859000
CY2023Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	292000
CY2024Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	6731000
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3155000
CY2024Q2	us-gaap	Inventory Net InventoryNet	5133000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5062000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3679000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2024000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	39340000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	47330000
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	6000
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	6000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1547000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	967000
CY2024Q2	drio	Long Term Assets Noncurrent LongTermAssetsNoncurrent	134000
CY2023Q4	drio	Long Term Assets Noncurrent LongTermAssetsNoncurrent	143000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1334000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	899000
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22346000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5404000
CY2024Q2	us-gaap	Goodwill Goodwill	57427000
CY2023Q4	us-gaap	Goodwill Goodwill	41640000
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	82794000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	49059000
CY2024Q2	us-gaap	Assets Assets	122134000
CY2023Q4	us-gaap	Assets Assets	96389000
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3351000
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1131000
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1515000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	997000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	884000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	111000
CY2024Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6475000
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6300000
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5191000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3954000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17416000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12493000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1118000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	885000
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23440000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24591000
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	12054000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	240000
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	51000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	36000
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	36663000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	25752000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30024275
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27191849
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	40331
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	18959
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	431526000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	407502000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-363474000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349361000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	68055000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	58144000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122134000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96389000
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6255000
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6152000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12013000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13218000
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3499000
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4078000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6825000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7976000
CY2024Q2	us-gaap	Gross Profit GrossProfit	2756000
CY2023Q2	us-gaap	Gross Profit GrossProfit	2074000
	us-gaap	Gross Profit GrossProfit	5188000
	us-gaap	Gross Profit GrossProfit	5242000
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6810000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5222000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13452000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10387000
CY2024Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	7132000
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	6460000
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	14042000
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	12800000
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5005000
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4412000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11740000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8483000
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	18947000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	16094000
	us-gaap	Operating Expenses OperatingExpenses	39234000
	us-gaap	Operating Expenses OperatingExpenses	31670000
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16191000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14020000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34046000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26428000
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2581000
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2565000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11267000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2982000
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13610000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16585000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22779000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29410000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1994000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13610000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16585000
	us-gaap	Net Income Loss NetIncomeLoss	-20785000
	us-gaap	Net Income Loss NetIncomeLoss	-29410000
CY2024Q2	drio	Other Comprehensive Income Loss Deemed Dividend Contribution OtherComprehensiveIncomeLossDeemedDividendContribution	-8706000
CY2023Q2	drio	Other Comprehensive Income Loss Deemed Dividend Contribution OtherComprehensiveIncomeLossDeemedDividendContribution	1691000
	drio	Other Comprehensive Income Loss Deemed Dividend Contribution OtherComprehensiveIncomeLossDeemedDividendContribution	-6672000
	drio	Other Comprehensive Income Loss Deemed Dividend Contribution OtherComprehensiveIncomeLossDeemedDividendContribution	1691000
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4904000
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18276000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14113000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31101000
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.58
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39830793
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39830793
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28186345
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28186345
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37778087
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37778087
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27879881
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27879881
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78033000
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2001000
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1561000
CY2024Q2	drio	Adjustments To Additional Paid In Capital Increase Decrease Warrant Modifications AdjustmentsToAdditionalPaidInCapitalIncreaseDecreaseWarrantModifications	70000
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13610000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	68055000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	58144000
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2028000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8392000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20206000
	drio	Adjustments To Additional Paid In Capital Increase Decrease Warrant Modifications AdjustmentsToAdditionalPaidInCapitalIncreaseDecreaseWarrantModifications	70000
	us-gaap	Net Income Loss NetIncomeLoss	-20785000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	68055000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	72030000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	595000
CY2023Q2	drio	Adjustments To Additional Paid In Capital Warrant Issued Related To Loan Agreement AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedToLoanAgreement	1389000
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4697000
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16278000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16585000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	78404000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	79999000
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1225000
	drio	Adjustments To Additional Paid In Capital Warrant Issued Related To Loan Agreement AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedToLoanAgreement	1389000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8923000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16278000
	us-gaap	Net Income Loss NetIncomeLoss	-29410000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	78404000
	us-gaap	Profit Loss ProfitLoss	-20785000
	us-gaap	Profit Loss ProfitLoss	-29410000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	10420000
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	10148000
	us-gaap	Depreciation Depreciation	648000
	us-gaap	Depreciation Depreciation	191000
	drio	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-425000
	drio	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-135000
	drio	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	2516000
	drio	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	2238000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	247000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1595000
	drio	Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets	-1171000
	drio	Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets	-476000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	71000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2042000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-190000
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-871000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3034000
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-865000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-224000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-531000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-417000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-90000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12643000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	204000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1501000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-96000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24473000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14393000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220000
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	4996000
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	5033000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8796000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8881000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-183000
	drio	Proceeds From Issuance Of Common Stock Preferred Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants	1410000
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	20206000
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	14868000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	29604000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	27833000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20206000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18049000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13148000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3473000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-48000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36797000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49470000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23601000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52943000
	us-gaap	Interest Paid Net InterestPaidNet	1972000
	us-gaap	Interest Paid Net InterestPaidNet	2044000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	428000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14000
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-363474000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24473000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 17.85pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="font-family:'Helvetica';font-size:8pt;margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 17.85pt;">Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. These estimates are based on management's knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.</p>
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22938000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52602000
CY2024Q2	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	663000
CY2023Q2	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	341000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23601000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52943000
	drio	Revenue Payment Terms RevenuePaymentTerms	P45D
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 17.85pt;">e. Concentrations of credit risk:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 34.85pt;">Financial instruments that potentially subject the Company to credit risks primarily consist of cash and cash equivalents, short-term deposits, restricted deposits, and trade receivables. For cash and cash equivalents, the Company is exposed to credit risks in the event of default by the financial institutions to the extent that amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 34.85pt;">For trade receivables, the Company is exposed to credit risk in the event of non-payment by customers to the extent of the amounts recorded on the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Balance at</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Balance at</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Deduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">end of period</p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Six months ended June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allowance for credit losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 214</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allowance for credit losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 163</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 34.85pt;">The Company has no off-balance-sheet concentration of credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 34.85pt;">As of June 30, 2024, the Company's major customer accounted for 29.7% of the Company's accounts receivable balance. For the three and six-month ended June 30, 2024, the Company's major customer accounted for 30.4% and 23.7% and respectively, of the Company's revenue in the period.</p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	163000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	120000
	drio	Accounts Receivable Allowance For Credit Loss Deductions AccountsReceivableAllowanceForCreditLossDeductions	-69000
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	214000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	140000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	163000
CY2024Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	418000
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	823000
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1015000
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4310000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4047000
CY2024Q2	us-gaap	Inventory Net InventoryNet	5133000
CY2023Q4	us-gaap	Inventory Net InventoryNet	5062000
	us-gaap	Inventory Write Down InventoryWriteDown	101000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	121000
	drio	Reduction In Revenue Per Agreement ReductionInRevenuePerAgreement	1088000
CY2024Q2	drio	Reduction In Revenue Per Agreement ReductionInRevenuePerAgreement	1088000
CY2022Q3	drio	Aggregative Consideration AggregativeConsideration	2650000
CY2023Q1	drio	Aggregative Consideration AggregativeConsideration	90000
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6255000
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6152000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12013000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13218000
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1426000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	997000
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	742000
CY2024Q2	drio	New Performance Obligations NewPerformanceObligations	1659000
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	-1883000
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1515000
CY2024Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	258000
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	238000
CY2024Q2	us-gaap	Deferred Costs DeferredCosts	79000
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	59000
CY2024Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	337000
CY2023Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	297000
CY2023Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	297000
	drio	Deferred Costs Additions DeferredCostsAdditions	126000
	drio	Deferred Costs Decrease DeferredCostsDecrease	86000
CY2024Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	337000
CY2023Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	30000000
CY2024Q2	drio	Fair Value Adjustments Proceeds Allocated To Loan FairValueAdjustmentsProceedsAllocatedToLoan	28215000
CY2024Q2	drio	Fair Value Adjustments Proceeds Allocated To Warrants FairValueAdjustmentsProceedsAllocatedToWarrants	1389000
CY2023Q2	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	30000000
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1413000
CY2023Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0450
CY2023Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1250
CY2024Q2	drio	Interest Rate Default Event Over Applicable Interest Rate InterestRateDefaultEventOverApplicableInterestRate	0.0500
CY2024Q2	us-gaap	Debt Instrument Measurement Input DebtInstrumentMeasurementInput	0.19
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	24457000
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-9156000
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	15301000
CY2024Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	36771000
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	17312000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14425000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11908000
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22346000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5404000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2516000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4512000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2581000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3869000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2820000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2994000
CY2024Q2	drio	Finite Lived Intangible Asset Expected Amortization After Year Three FiniteLivedIntangibleAssetExpectedAmortizationAfterYearThree	10082000
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22346000
CY2022Q4	us-gaap	Goodwill Goodwill	41640000
CY2023Q4	us-gaap	Goodwill Goodwill	41640000
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	15787000
CY2024Q2	us-gaap	Goodwill Goodwill	57427000
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1471250
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2550829
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	36000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7198759
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.93
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4688
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	165222
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	20.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	686562
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.02
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8893116
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M1D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7292573
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M8D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	19000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2897718
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M15D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19000
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10733000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y11M1D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10420000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10148000
	drio	Bank Charges BankCharges	45000
	drio	Bank Charges BankCharges	65000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	68000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-105000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	729000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	864000
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	37000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-2058000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3456000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12643000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-246000
	drio	Liabilities Fair Value Adjustment Warrant Modification LiabilitiesFairValueAdjustmentWarrantModification	70000
CY2023Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	503000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11267000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2982000
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33782788
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32875394
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12195745
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12195745
CY2023Q2	us-gaap	Undistributed Earnings UndistributedEarnings	16338276
	us-gaap	Undistributed Earnings UndistributedEarnings	28849228
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28186345
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27879881
CY2023Q2	us-gaap	Earnings Per Share Basic Undistributed EarningsPerShareBasicUndistributed	0.58
	us-gaap	Earnings Per Share Basic Undistributed EarningsPerShareBasicUndistributed	1.03
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03

Files In Submission

Name	View Source	Status
0001558370-24-011453-index-headers.html	Edgar Link	pending
0001558370-24-011453-index.html	Edgar Link	pending
0001558370-24-011453.txt	Edgar Link	pending
0001558370-24-011453-xbrl.zip	Edgar Link	pending
drio-20240630.xsd	Edgar Link	pending
drio-20240630x10q.htm	Edgar Link	pending
drio-20240630xex31d1.htm	Edgar Link	pending
drio-20240630xex31d2.htm	Edgar Link	pending
drio-20240630xex32d1.htm	Edgar Link	pending
drio-20240630xex32d2.htm	Edgar Link	pending
drio-20240630xex4d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
drio-20240630_def.xml	Edgar Link	unprocessable
drio-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
drio-20240630x10q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
drio-20240630_cal.xml	Edgar Link	unprocessable
drio-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2024 Q3 Form 10-Q Financial Statement

#000155837024011453 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2024 Q3 Form 10-Q Financial Statement

#000155837024011453 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio